Business Context and Reporting Period
This Form 8-K filing by 60 Degrees Pharmaceuticals, Inc. (SXTP) covers the period ending February 11, 2026. The report addresses a regulatory matter concerning the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is a $20,000 hearing fee paid by the company to appeal a potential delisting.
Material Changes
The primary material event is the resolution of a delisting threat. On January 20, 2026, the company received notice of potential delisting due to failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. As of February 11, 2026, the company has regained compliance with Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Resolution: The scheduled hearing before the Nasdaq Hearings Panel for February 19, 2026, has been cancelled, and the matter is closed.
- Listing Status: The company's common stock and warrants will continue to be listed and traded on The Nasdaq Capital Market.
- Risk Mitigation: The immediate risk of delisting due to low bid price has been resolved for the current period.
Investor Verification Checklist
- Verify the current trading price of SXTP to ensure it remains above the $1.00 minimum bid price threshold.
- Confirm the continued listing status of both the common stock (SXTP) and warrants (SXTPW) on Nasdaq.
- Review subsequent filings for any new compliance notices regarding bid price or other listing standards.